Fig. 1
From: Glaucocalyxin A alleviates ulcerative colitis by inhibiting PI3K/AKT/mTOR signaling
Glaucocalyxin A alleviates symptoms of DSS-induced acute colitis in wild-type mice. (A) Design approach. (B) Changes in body weight of mice at 0–7 days. (C) Mouse DAI score. (D) Comparison of colon length in mice. (E) Statistical chart of mouse colon length. (F) Colon sections stained with H&E in different treatment groups. (G) H&E score statistics of mice. (###p< 0.05 relative to the NC group; *p < 0.05, **p< 0.01, and ***p < 0.001 relative to the DSS group) (n = 10 mice per group).
